We are live on ! Find out more
MITO

Stealth BioTherapeutics Corp. ADS
MITO

Delisted

MITO was delisted on the 15th of November, 2022.

Back to rankings

13 hedge funds and large institutions have $638K invested in Stealth BioTherapeutics Corp. ADS in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

13% less funds holding

Funds holding: 15 → 13 (-2)

15% less capital invested

Capital invested by funds: $752K → $638K (-$114K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$17.2K
2
IC
Ikarian Capital
Texas
+$15.7K
3
Citigroup
Citigroup
New York
+$4.05K
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$1.22K
5
Osaic Holdings
Osaic Holdings
Arizona
+$1K

Top Sellers

Rank Fund Capital Flow
1
GSC
Ground Swell Capital
South Carolina
-$16K
2
Citadel Advisors
Citadel Advisors
Florida
-$13K
3
Renaissance Technologies
Renaissance Technologies
New York
-$7.08K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$5.95K
5
Millennium Management
Millennium Management
New York
-$1.04K

MITO Hedge Fund Activity: Q1 2022 in Review

13 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q1 2022, worth a combined $638K — down 15% from $752K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of MITO and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Geode Capital Management, adding an estimated $17.2K. The largest seller was Ground Swell Capital, exiting entirely with an estimated $16K sold.

  • 13 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q1 2022, down from 15 in Q4 2021.
  • Funds reported $638K of Stealth BioTherapeutics Corp. ADS stock for Q1 2022, down 15% quarter-over-quarter.
  • 1 fund opened new Stealth BioTherapeutics Corp. ADS positions in Q1 2022 and 3 closed out, a net change of -2 holders.
  • The largest Stealth BioTherapeutics Corp. ADS buyer in Q1 2022 was Geode Capital Management, an estimated $17.2K added.
  • The largest Stealth BioTherapeutics Corp. ADS seller in Q1 2022 was Ground Swell Capital, an estimated $16K sold.

Based on aggregated 13F filings for Q1 2022.